Latest Content

Oncology nurses can advocate for safe antacid use to prevent unnecessary therapy and optimize outcomes.

FDA approved belzutifan plus pembrolizumab for adjuvant clear cell renal cell carcinoma at high risk of recurrence following nephrectomy.

Michael Adashek, DO, explores why oncology providers must prioritize cascade testing to protect patients’ families from hereditary cancer risks.

Discover how oncology nurses can make a profound impact beyond the bedside by registering as stem cell and bone marrow donors to save lives.

Celebrating 25 years, Dana-Farber’s Cantor Center integrates oncology nursing science into clinical practice to improve patient quality of life.

New research finds extreme heat causes cancer patients to skip appointments and reduce activity, highlighting a need for clinical heat-risk planning.

Experts discuss how body image, fatigue, and shifting relationship roles impact sexual health and intimacy for patients undergoing cancer care.

Dr. Loren Rourke discusses how GLP-1s may impact breast cancer risk by reducing adipose tissue-derived estrogen and chronic metabolic inflammation.

Olympic legend Shannon Miller reflects on her 15-year ovarian cancer journey and why oncology nurses are the key to breaking patient silence.

Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC.

Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.

ASCO 2026 research highlights GLP-1 medications as a potential breast cancer prevention tool, showing a 30% risk reduction in retrospective analysis.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.